<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>44</volume><submitter>Wu Y</submitter><pubmed_abstract>Cisplatin resistance plays a significant role in the dismal prognosis and progression of muscle-invasive bladder cancer (MIBC). However, the strategies to predict prognosis and cisplatin resistance are inefficient, and it remains unclear whether cisplatin resistance is associated with tumor immunity. In this study, we integrated the transcriptional data from cisplatin-resistant cell lines and a TCGA-MIBC cohort to establish cisplatin-resistance-related cluster classification and a cisplatin-resistance-related gene risk score (CRRGRS). Kaplan-Meier survival curves showed that compared with those in low CRRGRS group, MIBC patients belonging to high CRRGRS group had worse prognosis in TCGA-MIBC cohort and external GEO cohorts. Meanwhile, CRRGRS was able to help forecast chemotherapy and immun</pubmed_abstract><journal>Translational oncology</journal><pagination>101942</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10990904</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBC.</pubmed_title><pmcid>PMC10990904</pmcid><pubmed_authors>Tian J</pubmed_authors><pubmed_authors>Jin B</pubmed_authors><pubmed_authors>Fu G</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Xu Z</pubmed_authors><pubmed_authors>Cai H</pubmed_authors><pubmed_authors>Jiang P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBC.</name><description>Cisplatin resistance plays a significant role in the dismal prognosis and progression of muscle-invasive bladder cancer (MIBC). However, the strategies to predict prognosis and cisplatin resistance are inefficient, and it remains unclear whether cisplatin resistance is associated with tumor immunity. In this study, we integrated the transcriptional data from cisplatin-resistant cell lines and a TCGA-MIBC cohort to establish cisplatin-resistance-related cluster classification and a cisplatin-resistance-related gene risk score (CRRGRS). Kaplan-Meier survival curves showed that compared with those in low CRRGRS group, MIBC patients belonging to high CRRGRS group had worse prognosis in TCGA-MIBC cohort and external GEO cohorts. Meanwhile, CRRGRS was able to help forecast chemotherapy and immun</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-18T20:15:08.122Z</modification><creation>2025-04-07T08:09:49.126Z</creation></dates><accession>S-EPMC10990904</accession><cross_references><pubmed>38555741</pubmed><doi>10.1016/j.tranon.2024.101942</doi></cross_references></HashMap>